On November 17, Hims & Hers Health Inc. fell 5.01% in Regular Trading, trading at $17.5734 per share, with turnover of $62.2822 million.
The move was tied to continued pressure from the company’s weaker-than-expected third-quarter results, softer fourth-quarter and full-year revenue guidance, and an expanded FTC case that added five states as co-plaintiffs.
Recent results showed a third-quarter loss of $0.14 per share, versus market expectations for a profit, while revenue of $890.4 million also came in slightly below consensus. The company guided fourth-quarter revenue to $875 million-$895 million, below expectations of $953.8 million, and narrowed its full-year revenue outlook to $3.13 billion-$3.15 billion, also below consensus. Separately, the FTC’s revised complaint broadened scrutiny around sensitive health information handling, billing, and subscription cancellation practices, reinforcing risk aversion toward the shares.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments